The US presidential election process has crystallized into a rematch between Joe Biden and Donald Trump and so drug pricing reform will be an ongoing concern for industry.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.
